Targeting AT2 Receptors in Renal Disease
Tianxin Yang
DOI: https://doi.org/10.1152/ajprenal.00142.2021
2021-01-01
American Journal of Physiology - Renal Physiology
Abstract:EditorialTargeting AT2 receptors in renal diseaseTianxin YangTianxin YangInternal Medicine, University of Utah, Salt Lake City, UtahVeterans Affairs Medical Center, Salt Lake City, UtahPublished Online:02 Jun 2021https://doi.org/10.1152/ajprenal.00142.2021This is the final version - click for previous versionMoreSectionsPDF (255 KB)Download PDFDownload PDFPlus ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmail The renin-angiotensin system (RAS) plays a pivotal role in the maintenance of homeostasis of fluid and electrolytes as well as blood pressure (BP), and inappropriate activation of this system leads to an elevation of BP (1). Apart from the physiological function, activation of the RAS contributes to the pathogenesis of renal disease, an effect that can be independent of BP. Indeed, angiotensin II (ANG II) exerts direct proinflammatory prooxidant and fibrotic responses implicated in multiple disease processes including various types of renal disease in addition to its pathogenic role in hypertension. Recent evidence demonstrates that activation of the intrarenal RAS in a variety of animal models of renal disease such as 5/6th nephropathy, adriamycin nephropathy, unilateral ureteral obstruction, and polycystic kidney disease is an important driver of the disease progression (2–5). Along this line, RAS inhibition with angiotensin-converting enzyme (ACE) inhibitors or ANG II type 1 receptor (AT1R) blockers remains the cornerstone therapy for hypertension as well as various types of renal disease. However, inhibition of the deteriorative axis of the RAS is only suboptimal. For example, this strategy is associated with hyperreninemia (6) as well as other side effects. More importantly, it cannot stop the progress of renal injury to end-stage renal disease, calling for more effective alternative therapeutic options.ANG II acts on two distinct types of receptors: AT1R and ANG II type 2 receptors (AT2R). As opposed to the proinflammatory, prooxidant, profibrotic, and prohypertensive actions of AT1R, activation of AT2R elicits anti-inflammatory, antioxidant, antifibrotic, and antihypertensive responses, representing a main receptor of the protective arm of the RAS (7). As a result, attention has shifted toward enhancing the protective arm of the RAS by AT2R agonism or activation of the ACE2/ANG(1−7)/Mas axis rather than inhibition of the AT1R-mediated deteriorative axis of this system. In support of this notion, the renoprotective action of AT2R agonism has been consistently demonstrated in a number of animal models of chronic kidney disease (CKD) (8–11) as well as acute kidney injury (AKI) (12).In 2004, the first nonpeptide AT2R agonist, named C21, was developed as a highly specific and orally and systemically active activator of AT2R, offering a novel reagent for AT2R research (13). The availability of this reagent has greatly facilitated understanding the properties and function of AT2R. C21, modeled on the COOH-terminal pentapeptide structure of ANG II, exhibited 4,000-fold selectivity for AT2R over AT1R in human embryonic kidney cells (14, 15). C21 showed a profound renoprotective effect in ameliorating albuminuria, inflammation, oxidant stress, and tubulointerstitial fibrosis in Zucker obese rats (16) as well as doxorubicin-induced (17) and cyclosporine-induced (18) nephropathy. Of particular interest, despite the well-known natriuretic and antihypertensive properties of AT2R, C21 did not affect BP in high-salt diet-fed stroke-prone spontaneously hypertensive rats but reduced proteinuria, glomerular and tubular damage, and immune cell infiltration as well as vascular lesion, indicating BP-independent effects (19). Interestingly, C21 massively reduced plasma renin activity, contrasting to hyperreninemia seen with ACE inhibition or AT1R blockers. The renin-inhibitory property of C21 may overcome the long-sought issue of hyperreninemia induced by existing RAS inhibitors. Another AT2R agonist, CGP-42112A, led to similar beneficial effects on renal inflammation and oxidative stress in obese Zucker rats, substantiating the involvement of AT2R (20). It is important to note that the beneficial effects of AT2R agonism have been demonstrated in disease processes of extrarenal organs such as heart failure, myocardial infarction, chronic inflammatory diseases, and neurological diseases such as ischemic stroke (21, 22).AKI, also known as acute renal failure, features a sudden episode of kidney damage and a rapid decline of renal function within hours or days. Although the cause of AKI is multifactorial, nonseptic ischemia-reperfusion (I/R) injury accounts for the majority of the cases due to trauma, surgeries, and organ transplantation, associated with high mortality and morbidity. The pathophysiology of AKI may be composed of multiple components including alteration of renal hemodynamics and inflammation/immunity, all of which may be consequences of overactivation of the RAS. The compromised renal hemodynamics including reduced glomerular filtration rate and renal blood flow in AKI can be the direct consequence of ANG II-induced vasoconstriction. In addition, AKI is often associated with increased infiltration of multiple inflammatory and immune cells including polymorphonuclear cells and monocytes/macrophages, dendritic cells, natural killer cells, B cells, and T cells, some or most of which depend on activation of the RAS (23). Although the renoprotective role of AT2R in CKD has been well demonstrated (9, 16), less is known about its potential role in AKI. In an article recently published in the American Journal of Physiology-Renal Physiology, Ali et al. (24) investigated the potential renoprotective effect of C21 in a rat model of renal I/R injury and further explored the underlying mechanism by vigorous examination of infiltrating T cells and the cytokine profile. C21 was given at 0.3 mg/kg via intraperitoneal injection 2 h before ischemic surgery, and animals were followed for 2 h, 3 days, or 5 days; for the last two time points, the same dose of C21 was given once a day. This study design allows assessment of the therapeutic potential of C21 at both the acute injury phase (2 h) and the chronic repair phase (3 and 5 days). The preventative C21 administration nearly completely normalized renal dysfunction during the acute injury phase. The functional improvement parallels the amelioration of infiltrating hematopoietic cells (CD45+ cells) and CD3+ and CD4+ T cells; production of proinflammatory cytokines including monocyte chemoattractant protein-1, IL-6, and TNF-α; and enhancement of anti-inflammatory IL-10. These results suggest that AT2R may modulate T cells to elicit a renoprotective action during the acute phase. During the chronic phase (3 and 5 days), renal function returned to the normal range, and the repair response was activated, as highlighted by increased CD4+Foxp3 cells [regulatory T (Treg) cells]. The percentage of Treg cells was further enhanced by C21. It seems likely that AT2R may promote repair during the chronic phase. In agreement with the current observation, an earlier study from the same group reported that C21 attenuates lipopolysaccharide-induced early infiltration of renal infiltration of CD11b+ immune cells, production of IL-6 and monocyte chemoattractant protein-1, and renal dysfunction (12). The similar findings obtained from two different models (I/R and lipopolysaccharide) have substantiated the renoprotective action of AT2R in AKI and also the involvement of T cells.There are a number of unanswered questions. For example, what is the cellular mechanism of how AT2R activation affords renoprotection? Known mediators downstream of AT2R include nitric oxide, cGMP, or protein phosphatase 2 A (25, 26). Which of these mediators is responsible for the renoprotective action of AT2R? The authors showed that AT2R is capable of modulating T cells. However, what is the relative importance of T cell modulation versus other mechanisms such as alteration of renal hemodynamics in mediating renoprotective action of AT2R? Enhanced vasoconstriction and the subsequent reduction of renal blood flow likely play a significant role in the rapid decline of renal function during the acute phase of AKI (2 h). AT2R is well known to be a vasodilator, and its activation in AKI will improve renal hemodynamics and thus renal function.Is there any role of endogenous AT2R signaling in AKI? This issue can be ideally addressed to test if AT2R deletion accelerates disease progression compared with wild-type controls. In fact, a number of studies have used AT2R knockout animals to demonstrate the renoprotective role of AT2R in mouse models of CKD including unilateral urethral obstruction (27), 5/6th nephrectomy (28), and streptozotocin-induced diabetic nephropathy (29). In the context of endogenous AT2R signaling in AKI, one may wonder how renal expression or activity of AT2R is altered during renal I/R injury. What is the cellular localization of altered AT2R expression? Angiotensin III, the degradation product of ANG II, is considered as a physiological ligand of AT2R (30). It is highly desirable to understand the status of generation of angiotensin III along with other components of the RAS during renal I/R injury.In conclusion, compelling preclinical evidence demonstrates a protective role of AT2R activation by C21 in animal models of AKI as well as CKD and paves the way for future clinical trials of this compound for the management of renal disease. The mechanism of AT2R-mediated renoprotection in renal I/R injury involves modulation of T cells with suppression of proinflammatory cytokines during the acute phase and enhancement of anti-inflammatory cytokines during the repair phase (Fig. 1). The detailed signaling pathway upstream and downstream of AT2R in AKI awaits future investigation.Figure 1.Illustration of the dual roles of the angiotensin II type 2 receptor (AT2R) during renal ischemia-reperfusion (I/R) injury. Activation of AT2R by C21 suppresses the proinflammatory immune response and release of TNF-α and IL-6 during the acute phase but promotes the anti-inflammatory immune response to facilitate the repair process during the chronic phase. Tregs, regulatory T cells.Download figureDownload PowerPointGRANTSThis work was supported by National Institutes of Health Grants HL139689, DK104072, and HL135851 and Veterans Affairs Merit Review Awards from the United States Department of Veterans Affairs (Grants I01BX004871 and ik6BX005223). T.Y. is a Senior Research Career Scientist in the Department of Veterans Affairs.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONST.Y. conceived and designed research; T.Y. drafted manuscript; T.Y. edited and revised manuscript; T.Y. approved final version of manuscript.REFERENCES1. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension 57: 355–362, 2011. doi:10.1161/HYPERTENSIONAHA.110.163519. Crossref | PubMed | ISI | Google Scholar2. Graciano ML, Cavaglieri RC, Delle H, Dominguez WV, Casarini DE, Malheiros DM, Noronha IL. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 15: 1805–1815, 2004. doi:10.1097/01.ASN.0000131528.00773.A9.Crossref | PubMed | ISI | Google Scholar3. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125: 1402–1413, 2012. doi:10.1161/CIRCULATIONAHA.111.064097. Crossref | PubMed | ISI | Google Scholar4. Saigusa T, Dang Y, Bunni MA, Amria MY, Steele SL, Fitzgibbon WR, Bell PD. Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease. Physiol Rep 3: e12405, 2015. doi:10.14814/phy2.12405.Crossref | PubMed | Google Scholar5. Zhou L, Mo H, Miao J, Zhou D, Tan RJ, Hou FF, Liu Y. Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system. Am J Pathol 185: 3211–3223, 2015. doi:10.1016/j.ajpath.2015.08.004. Crossref | PubMed | ISI | Google Scholar6. Pals DT, Couch SJ. Renin release induced by losartan (DuP 753), an angiotensin II receptor antagonist. Clin Exp Hypertens 15: 1–13, 1993. doi:10.3109/10641969309041609. Crossref | PubMed | ISI | Google Scholar7. Carey RM. AT2 receptors: potential therapeutic targets for hypertension. Am J Hypertens 30: 339–347, 2017. doi:10.1093/ajh/hpw121. Crossref | PubMed | ISI | Google Scholar8. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514–1529, 2004. doi:10.1097/01.asn.0000130564.75008.f5. Crossref | PubMed | ISI | Google Scholar9. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 298: F683–F691, 2010. doi:10.1152/ajprenal.00503.2009. Link | ISI | Google Scholar10. Pandey A, Gaikwad AB. AT2 receptor agonist compound 21: a silver lining for diabetic nephropathy. Eur J Pharmacol 815: 251–257, 2017. doi:10.1016/j.ejphar.2017.09.036.Crossref | PubMed | ISI | Google Scholar11. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 24: 2417–2422, 2006. doi:10.1097/01.hjh.0000251902.85675.7e.Crossref | PubMed | ISI | Google Scholar12. Patel S, Dhande I, Gray EA, Ali Q, Hussain T. Prevention of lipopolysaccharide-induced CD11b(+) immune cell infiltration in the kidney: role of AT2 receptors. Biosci Rep 39: BSR20190429, 2019. doi:10.1042/BSR20190429.Crossref | PubMed | ISI | Google Scholar13. Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists–where should they be applied? Expert Opin Investig Drugs 21: 763–766, 2012. doi:10.1517/13543784.2012.681046. Crossref | PubMed | ISI | Google Scholar14. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121: 297–303, 2011. doi:10.1042/CS20110036. Crossref | PubMed | ISI | Google Scholar15. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995–6008, 2004. doi:10.1021/jm049715t. Crossref | PubMed | ISI | Google Scholar16. Patel SN, Ali Q, Hussain T. Angiotensin II type 2 receptor agonist C21 reduces proteinuria and oxidative stress in kidney of high-salt-fed obese Zucker rats. Hypertension 67: 906–915, 2016. doi:10.1161/HYPERTENSIONAHA.115.06881. Crossref | PubMed | ISI | Google Scholar17. Hrenak J, Arendasova K, Rajkovicova R, Aziriova S, Repova K, Krajcirovicova K, Celec P, Kamodyova N, Barta A, Adamcova M, Paulis L, Simko F. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiol Res 62: S181–189, 2013. doi:10.33549/physiolres.932614. Crossref | PubMed | ISI | Google Scholar18. Castoldi G, di Gioia CRT, Carletti R, Roma F, Zerbini G, Stella A. Angiotensin type-2 (AT-2) receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood pressure independent effect. Biosci Rep 36: e00403, 2016. doi:10.1042/BSR20160278.Crossref | PubMed | ISI | Google Scholar19. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59: 291–299, 2012. doi:10.1161/HYPERTENSIONAHA.111.180158.Crossref | PubMed | ISI | Google Scholar20. Sabuhi R, Ali Q, Asghar M, Al-Zamily NR, Hussain T. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 300: F700–F706, 2011. Link | ISI | Google Scholar21. Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, Bountra C, Korchev YE, Anand P. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 17: 1012–1026, 2013. doi:10.1002/j.1532-2149.2012.00269.x. Crossref | PubMed | ISI | Google Scholar22. Chow BS, Allen TJ. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci (Lond) 130: 1307–1326, 2016. doi:10.1042/CS20160243. Crossref | PubMed | ISI | Google Scholar23. Yamada T, Fujisaki T, Chopra N, Yamaji T, Azushima K, Kobayashi R, Kinguchi S, Urate S, Suzuki T, Abe E, Wakui H, Tamura K, Steinberg D. Effect of renin-angiotensin system blockers on contrast- induced acute kidney injury in patients with normal or mild-to-moderate reduced kidney function undergoing coronary angiography: a systematic review and meta-analysis. Clin Nephrol 94: 227–236, 2020. Crossref | PubMed | ISI | Google Scholar24. Ali R, Patel S, Hussain T. Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia. Am J Physiol Renal Physiol 320: F814–F825, 2021. doi:10.1152/ajprenal.00507.2020.Link | ISI | Google Scholar25. Carey RM. Blood pressure and the renal actions of AT2 receptors. Curr Hypertens Rep 19: 21, 2017. doi:10.1007/s11906-017-0720-7. Crossref | PubMed | ISI | Google Scholar26. Carey RM. Update on angiotensin AT2 receptors. Curr Opin Nephrol Hypertens 26: 91–96, 2017. doi:10.1097/MNH.0000000000000304. Crossref | PubMed | ISI | Google Scholar27. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53: 937–944, 1998. doi:10.1111/j.1523-1755.1998.00893.x. Crossref | PubMed | ISI | Google Scholar28. Benndorf RA, Krebs C, Hirsch-Hoffmann B, Schwedhelm E, Cieslar G, Schmidt-Haupt R, Steinmetz OM, Meyer-Schwesinger C, Thaiss F, Haddad M, Fehr S, Heilmann A, Helmchen U, Hein L, Ehmke H, Stahl RA, Boger RH, Wenzel UO. Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 75: 1039–1049, 2009. doi:10.1038/ki.2009.2. Crossref | PubMed | ISI | Google Scholar29. Chang S-Y, Chen Y-W, Chenier I, Tran SLM, Zhang S-L. Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res 2011: 521076, 2011. doi:10.1155/2011/521076. Crossref | PubMed | Google Scholar30. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res 125: 21–38, 2017. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESCorrespondence: T. Yang (Tianxin.[email protected]utah.edu). Previous Back to Top Next FiguresReferencesRelatedInformation More from this issue > Volume 320Issue 6June 2021Pages F1025-F1027 Crossmark Copyright & PermissionsPublished by the American Physiological Societyhttps://doi.org/10.1152/ajprenal.00142.2021PubMed33938241History Received 8 April 2021 Accepted 27 April 2021 Published online 2 June 2021 Published in print 1 June 2021 PDF download Metrics Downloaded 662 times